Active	Status	Sponsor type	Region	Phase	Filter
21 Active 11 Inactive 32 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Frey, Noelle
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study	Recruiting	3	1400	Europe, Canada, Japan, US, RoW	Previously treated CAR-T patients	Novartis Pharmaceuticals, University of Pennsylvania	Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program	02/36	02/36
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL	Recruiting	1/2	225	Europe, Japan, US, RoW	Rapcabtagene autoleucel single agent, Ibrutinib	Novartis Pharmaceuticals	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma	06/27	05/28
Dinner, Shira
NCT05289687: Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL	Recruiting	2	20	US	Daratumumab / Hyaluronidase Injection	Eastern Cooperative Oncology Group, Janssen, LP	T-cell Acute Lymphoblastic Leukemia	06/27	06/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL	Recruiting	1/2	225	Europe, Japan, US, RoW	Rapcabtagene autoleucel single agent, Ibrutinib	Novartis Pharmaceuticals	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma	06/27	05/28
Purri, Rachael
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL	Recruiting	1/2	225	Europe, Japan, US, RoW	Rapcabtagene autoleucel single agent, Ibrutinib	Novartis Pharmaceuticals	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma	06/27	05/28
Krieg, Holly Roberta
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL	Recruiting	1/2	225	Europe, Japan, US, RoW	Rapcabtagene autoleucel single agent, Ibrutinib	Novartis Pharmaceuticals	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma	06/27	05/28